ImmuntyBio Submits Biologics License Application for N-803 + BCG to Treat BCG-unresponsive NMIBC CIS
Shots:
- The BLA submission was based on the results from the P-I/II trial (n=171) & & P-II/III (QUILT 3032) study (n=84) evaluating N-803 + BCG in patients with bladder cancer
- The results from the QUILT 3032 study demonstrated that the combination therapy allows a greater chance of avoiding bladder removal in patients. Additionally, N-803 is also being evaluated under the QUILT 2005 study for the treatment of BCG-naïve NMIBC
- ImmunityBio’s N-803 + BCG has previously received BTD & FTD for the treatment of BCG-unresponsive NMIBC CIS
Ref: Businesswire | Image: ImmunityBio
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
